Autologous Cell Therapy Market By Therapeutic area (Cancer, Others), By End user (Hospitals, Cancer treatment centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Autologous Cell Therapy Market

Autologous cell therapy is an innovative therapeutic intervention in which patient’s own cells are used for treatment. Cells are cultured/engineered, expanded in-vitro, and re-introduced in patient’s body for treatment purpose. Patient specificity, no rejection by the immune system, and least risk of host & graft issues are major advantages of this therapy. Nowadays, cancer is common and a major portion of the population suffers from cancer. The cases of cancer have witnessed a rise, owing to increase in unhealthy lifestyle, aging, tobacco, sun exposure, radiation exposure, and uptake of chemicals in food & beverages. For instance, according to Leukemia and Lymphoma Society, in U.S. around 61,090 people were diagnosed with leukemia in 2021. In addition, around 397,501 people are living with or in remission from leukemia in the U.S. Thus, surge in cancer cases is expected to drive the market growth. Moreover, recent developments in autologous cell therapy has created innovative procedures, which is advancement in minimizing the risk throughout the manufacturing process are the upcoming autologous cell therapy market trends.

The autologous cell therapy such as autologous CAR-T cell therapy in which the T cells are collected from a patient are genetically modified ex vivo and re-injected into the patient. In addition, advantages of autologous therapies include low immunogenicity and the avoidance of graft-versus-host disease.

In addition, other factors that drive growth of global autologous cell therapy market include increase in incidences of neurological disorders (such as multiple sclerosis and Parkinson's disease) and autoimmune disorders. For instance, according to the Multiple Sclerosis Society, in 2019, around 1 million people were living with multiple sclerosis disorder across the globe. 

The autologous cell therapy market is driven by rise in incidences of chronic diseases such as autoimmune diseases, cancer, and blood disorders that boost growth of the market. In addition, major players are investing in development and commercialization of autologous cell therapy to decrease incidences of these disorders that fuel the growth of autologous cell therapy industry.

The autologous cell therapy market analysis is segmented into the therapeutic area, end user aand region. Depending on therapeutic area, the autologous cell therapy market size is bifurcated into cancer and others. The cancer segment exhibited highest growth in 2021, and is expected to remain dominant during the autologous cell therapy market forecast period, owing to rise in prevalence of different types cancer across the globe.

On the basis of end user, the autologous cell therapy market size is classified into hospitals and cancer treatment centers. The hospitals segment dominated the autologous cell therapy market share in 2021, owing to well-equipped infrastructure, higher buying power, rise in patient admission, and adoption of technologically advanced autologous cell therapy. In addition, increase in patient’s preference toward hospitals as it safely provides treatment under the observation of skilled physicians. Moreover, the cancer treatment centers segment is projected to register a CAGR of 21.6% during the forecast period owing to rise in number of cancer treatment centers due to surge in prevalence of cancer diseases and availability of a wide range of choice of treatment in some developing nations. 

For instance, according to National Cancer Institute (NCI), data published in U.S. 2019, there are 71 INC-Designated Cancer Centers, located in 36 states and the District of Columbia.

Region wise, North America had the highest autologous cell therapy market share in 2021, and is expected to maintain its lead during the forecast period owing to strong presence of key players, availability of approved therapeutics with higher adoption of autologous cell therapy, and huge amount of funding by governments & private firms for clinical trials. 

However, Asia-Pacific is expected to witness highest CAGR during the forecast period owing to availability of autologous cell treatments and rise in public awareness of their potential for treating chronic diseases among individuals and healthcare organizations.

Key findings of the study

•    By therapeutic area, the cancer segment was highest contributor to the autologous cell therapy industry. in 2021.

•    On the basis of end user, the hospitals segment was dominated the market in 2021. However, cancer treatment centers is anticipated to grow at the highest CAGR of 21.6% during the forecast period.

•    Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 22.3% during the forecast period.

Overview

The global autologous cell therapy market was valued at $4,307.06 million in 2021, and is projected to reach $29,049.87 million by 2031, registering a CAGR of 21.0% from 2022 to 2031.

Autologous cell therapy is a novel therapeutic approach that is patient-specific and involves isolating & developing cells before reinfusing them back into the same person (for CAR-T cell therapy, isolated cells are genetically modified before reintroduction). Autologous cell therapy reduces the systemic immunological reactions, bio-incompatibility, and disease transmission hazards connected to grafts or cells that were not grown from the individual. It is used for treating various cancer, musculoskeletal, dermatological, neurodegenerative, & cardiac diseases, and others disorders. 

The growth of global autologous cell therapy market is majorly driven by increase in demand for autologous cell therapy, owing to rise in R&D institutes & organizations for developing autologous cell therapy products and surge in chronic diseases especially cancer. For instance, in June 2020, FDA approved the product of Gilead Sciences Inc., Kite’s Tecartus, an autologous CAR T-cell treatment for relapsed or refractory mantle cell lymphoma. In addition, rise in neurodegenerative disorders and upsurge in musculoskeletal disorders globally drive the market. Increasing emphasis on the replacement or regeneration of human cells, tissues, and organs to restore normal functionality to repair or replace cells in human tissues and organs that have undergone injury or illness and become damaged or dysfunctional further drives demand for autologous cell therapy and boosts the market growth. It can be accomplished by promoting the body’s own cells to heal or by treating a patient with their own healthy cells. 

Furthermore, automation in adult stem cells and cord blood processing & storage are the key technological advancements that fuel growth of the autologous cell therapy market. However, high cost and lower treatment facilities associated with autologous cell therapy may hinder the market growth. Conversely, high growth potential in untapped economies is anticipated to provide lucrative opportunities to the market players.

The autologous cell therapy market is segmented on the basis of therapeutic area, end user, and region. By therapeutic area, the market is bifurcated into cancer and others. The cancer segment is further categorized into lymphoma, acute lymphocytic leukemia, and others. On the basis of end user, the market is segregated into hospitals and cancer treatment centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

Major key players that operate in the autologous cell therapy market are Bristol Myers Squibb, CORESTEM, Inc., GC Biopharma Corp (GC Cell), Gilead Sciences, Inc. (Kite Pharma, Inc.), Holostem Terapie Avanzate S.r.l., Johnson & Johnson Private Limited (Janssen Biotech, Inc), Novartis AG, Sanpower Group (Dendreon Pharmaceuticals LLC.), Tego Science, and Vericel Corporation.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autologous cell therapy market analysis from 2021 to 2031 to identify the prevailing autologous cell therapy market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the autologous cell therapy market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global autologous cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ CORESTEM, In

Scope of Autologous Cell Therapy Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Cancer

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.2.4 Cancer Autologous Cell Therapy Market by Type

4.3 Others

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Hospitals

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Cancer treatment centers

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by Therapeutic area

6.2.3 North America Market size and forecast, by End user

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Key market trends, growth factors and opportunities

6.2.4.1.2 Market size and forecast, by Therapeutic area

6.2.4.1.3 Market size and forecast, by End user

6.2.4.2 Canada

6.2.4.2.1 Key market trends, growth factors and opportunities

6.2.4.2.2 Market size and forecast, by Therapeutic area

6.2.4.2.3 Market size and forecast, by End user

6.2.4.3 Mexico

6.2.4.3.1 Key market trends, growth factors and opportunities

6.2.4.3.2 Market size and forecast, by Therapeutic area

6.2.4.3.3 Market size and forecast, by End user

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by Therapeutic area

6.3.3 Europe Market size and forecast, by End user

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Key market trends, growth factors and opportunities

6.3.4.1.2 Market size and forecast, by Therapeutic area

6.3.4.1.3 Market size and forecast, by End user

6.3.4.2 France

6.3.4.2.1 Key market trends, growth factors and opportunities

6.3.4.2.2 Market size and forecast, by Therapeutic area

6.3.4.2.3 Market size and forecast, by End user

6.3.4.3 UK

6.3.4.3.1 Key market trends, growth factors and opportunities

6.3.4.3.2 Market size and forecast, by Therapeutic area

6.3.4.3.3 Market size and forecast, by End user

6.3.4.4 Italy

6.3.4.4.1 Key market trends, growth factors and opportunities

6.3.4.4.2 Market size and forecast, by Therapeutic area

6.3.4.4.3 Market size and forecast, by End user

6.3.4.5 Spain

6.3.4.5.1 Key market trends, growth factors and opportunities

6.3.4.5.2 Market size and forecast, by Therapeutic area

6.3.4.5.3 Market size and forecast, by End user

6.3.4.6 Rest of Europe

6.3.4.6.1 Key market trends, growth factors and opportunities

6.3.4.6.2 Market size and forecast, by Therapeutic area

6.3.4.6.3 Market size and forecast, by End user

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by Therapeutic area

6.4.3 Asia-Pacific Market size and forecast, by End user

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 Japan

6.4.4.1.1 Key market trends, growth factors and opportunities

6.4.4.1.2 Market size and forecast, by Therapeutic area

6.4.4.1.3 Market size and forecast, by End user

6.4.4.2 China

6.4.4.2.1 Key market trends, growth factors and opportunities

6.4.4.2.2 Market size and forecast, by Therapeutic area

6.4.4.2.3 Market size and forecast, by End user

6.4.4.3 India

6.4.4.3.1 Key market trends, growth factors and opportunities

6.4.4.3.2 Market size and forecast, by Therapeutic area

6.4.4.3.3 Market size and forecast, by End user

6.4.4.4 Australia

6.4.4.4.1 Key market trends, growth factors and opportunities

6.4.4.4.2 Market size and forecast, by Therapeutic area

6.4.4.4.3 Market size and forecast, by End user

6.4.4.5 South Korea

6.4.4.5.1 Key market trends, growth factors and opportunities

6.4.4.5.2 Market size and forecast, by Therapeutic area

6.4.4.5.3 Market size and forecast, by End user

6.4.4.6 Rest of Asia-Pacific

6.4.4.6.1 Key market trends, growth factors and opportunities

6.4.4.6.2 Market size and forecast, by Therapeutic area

6.4.4.6.3 Market size and forecast, by End user

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by Therapeutic area

6.5.3 LAMEA Market size and forecast, by End user

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Latin America

6.5.4.1.1 Key market trends, growth factors and opportunities

6.5.4.1.2 Market size and forecast, by Therapeutic area

6.5.4.1.3 Market size and forecast, by End user

6.5.4.2 Middle East And Africa

6.5.4.2.1 Key market trends, growth factors and opportunities

6.5.4.2.2 Market size and forecast, by Therapeutic area

6.5.4.2.3 Market size and forecast, by End user

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Key developments

8.1 Bristol Myers Squibb

8.1.1 Company overview

8.1.2 Company snapshot

8.1.3 Operating business segments

8.1.4 Product portfolio

8.1.5 Business performance

8.1.6 Key strategic moves and developments

8.2  Novartis

8.2.1 Company overview

8.2.2 Company snapshot

8.2.3 Operating business segments

8.2.4 Product portfolio

8.2.5 Business performance

8.2.6 Key strategic moves and developments

8.3 Vericel Corporation

8.3.1 Company overview

8.3.2 Company snapshot

8.3.3 Operating business segments

8.3.4 Product portfolio

8.3.5 Business performance

8.3.6 Key strategic moves and developments

8.4  Gilead Sciences (Kite Pharma, Inc.)

8.4.1 Company overview

8.4.2 Company snapshot

8.4.3 Operating business segments

8.4.4 Product portfolio

8.4.5 Business performance

8.4.6 Key strategic moves and developments

8.5  Johnson & Johnson(Janssen Biotech, Inc)

8.5.1 Company overview

8.5.2 Company snapshot

8.5.3 Operating business segments

8.5.4 Product portfolio

8.5.5 Business performance

8.5.6 Key strategic moves and developments

8.6 Tego Science

8.6.1 Company overview

8.6.2 Company snapshot

8.6.3 Operating business segments

8.6.4 Product portfolio

8.6.5 Business performance

8.6.6 Key strategic moves and developments

8.7 Sanpower Group (Dendreon Pharmaceuticals LLC.)

8.7.1 Company overview

8.7.2 Company snapshot

8.7.3 Operating business segments

8.7.4 Product portfolio

8.7.5 Business performance

8.7.6 Key strategic moves and developments

8.8 Holostem Terapie Avanzate S.r.l.

8.8.1 Company overview

8.8.2 Company snapshot

8.8.3 Operating business segments

8.8.4 Product portfolio

8.8.5 Business performance

8.8.6 Key strategic moves and developments

8.9 GC Biopharma (GC Cell)

8.9.1 Company overview

8.9.2 Company snapshot

8.9.3 Operating business segments

8.9.4 Product portfolio

8.9.5 Business performance

8.9.6 Key strategic moves and developments

8.10 CORESTEM, Inc

8.10.1 Company overview

8.10.2 Company snapshot

8.10.3 Operating business segments

8.10.4 Product portfolio

8.10.5 Business performance

8.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 2. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. GLOBAL CANCER AUTOLOGOUS CELL THERAPY MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 5. AUTOLOGOUS CELL THERAPY MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 6. AUTOLOGOUS CELL THERAPY MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 8. AUTOLOGOUS CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 9. AUTOLOGOUS CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 10. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 11. AUTOLOGOUS CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 12. AUTOLOGOUS CELL THERAPY MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 13. NORTH AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 14. NORTH AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 15. NORTH AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 16. U.S. AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 17. U.S. AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 18. CANADA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 19. CANADA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 20. MEXICO AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 21. MEXICO AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 22. EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 23. EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 24. EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 25. GERMANY AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 26. GERMANY AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 27. FRANCE AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 28. FRANCE AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 29. UK AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 30. UK AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 31. ITALY AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 32. ITALY AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 33. SPAIN AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 34. SPAIN AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 35. REST OF EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 36. REST OF EUROPE AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 37. ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 38. ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 39. ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 40. JAPAN AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 41. JAPAN AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 42. CHINA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 43. CHINA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 44. INDIA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 45. INDIA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 46. AUSTRALIA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 47. AUSTRALIA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 48. SOUTH KOREA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 49. SOUTH KOREA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 50. REST OF ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 51. REST OF ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 52. LAMEA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 53. LAMEA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 54. LAMEA AUTOLOGOUS CELL THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 55. LATIN AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 56. LATIN AMERICA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 57. MIDDLE EAST AND AFRICA AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)

TABLE 58. MIDDLE EAST AND AFRICA AUTOLOGOUS CELL THERAPY MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 59.BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 60.BRISTOL MYERS SQUIBB: OPERATING SEGMENTS

TABLE 61.BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 62.BRISTOL MYERS SQUIBB: NET SALES

TABLE 63.BRISTOL MYERS SQUIBB: KEY STRATERGIES

TABLE 64. NOVARTIS: COMPANY SNAPSHOT

TABLE 65. NOVARTIS: OPERATING SEGMENTS

TABLE 66. NOVARTIS: PRODUCT PORTFOLIO

TABLE 67. NOVARTIS: NET SALES

TABLE 68. NOVARTIS: KEY STRATERGIES

TABLE 69.VERICEL CORPORATION: COMPANY SNAPSHOT

TABLE 70.VERICEL CORPORATION: OPERATING SEGMENTS

TABLE 71.VERICEL CORPORATION: PRODUCT PORTFOLIO

TABLE 72.VERICEL CORPORATION: NET SALES

TABLE 73.VERICEL CORPORATION: KEY STRATERGIES

TABLE 74. GILEAD SCIENCES (KITE PHARMA, INC.): COMPANY SNAPSHOT

TABLE 75. GILEAD SCIENCES (KITE PHARMA, INC.): OPERATING SEGMENTS

TABLE 76. GILEAD SCIENCES (KITE PHARMA, INC.): PRODUCT PORTFOLIO

TABLE 77. GILEAD SCIENCES (KITE PHARMA, INC.): NET SALES

TABLE 78. GILEAD SCIENCES (KITE PHARMA, INC.): KEY STRATERGIES

TABLE 79. JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): COMPANY SNAPSHOT

TABLE 80. JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): OPERATING SEGMENTS

TABLE 81. JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): PRODUCT PORTFOLIO

TABLE 82. JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): NET SALES

TABLE 83. JOHNSON & JOHNSON(JANSSEN BIOTECH, INC): KEY STRATERGIES

TABLE 84.TEGO SCIENCE: COMPANY SNAPSHOT

TABLE 85.TEGO SCIENCE: OPERATING SEGMENTS

TABLE 86.TEGO SCIENCE: PRODUCT PORTFOLIO

TABLE 87.TEGO SCIENCE: NET SALES

TABLE 88.TEGO SCIENCE: KEY STRATERGIES

TABLE 89.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): COMPANY SNAPSHOT

TABLE 90.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): OPERATING SEGMENTS

TABLE 91.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): PRODUCT PORTFOLIO

TABLE 92.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): NET SALES

TABLE 93.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.): KEY STRATERGIES

TABLE 94.HOLOSTEM TERAPIE AVANZATE S.R.L.: COMPANY SNAPSHOT

TABLE 95.HOLOSTEM TERAPIE AVANZATE S.R.L.: OPERATING SEGMENTS

TABLE 96.HOLOSTEM TERAPIE AVANZATE S.R.L.: PRODUCT PORTFOLIO

TABLE 97.HOLOSTEM TERAPIE AVANZATE S.R.L.: NET SALES

TABLE 98.HOLOSTEM TERAPIE AVANZATE S.R.L.: KEY STRATERGIES

TABLE 99.GC BIOPHARMA (GC CELL): COMPANY SNAPSHOT

TABLE 100.GC BIOPHARMA (GC CELL): OPERATING SEGMENTS

TABLE 101.GC BIOPHARMA (GC CELL): PRODUCT PORTFOLIO

TABLE 102.GC BIOPHARMA (GC CELL): NET SALES

TABLE 103.GC BIOPHARMA (GC CELL): KEY STRATERGIES

TABLE 104.CORESTEM, INC: COMPANY SNAPSHOT

TABLE 105.CORESTEM, INC: OPERATING SEGMENTS

TABLE 106.CORESTEM, INC: PRODUCT PORTFOLIO

TABLE 107.CORESTEM, INC: NET SALES

TABLE 108.CORESTEM, INC: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.AUTOLOGOUS CELL THERAPY MARKET SEGMENTATION

FIGURE 2.AUTOLOGOUS CELL THERAPY MARKET,2021-2031

FIGURE 3.AUTOLOGOUS CELL THERAPY MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.AUTOLOGOUS CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.AUTOLOGOUS CELL THERAPY MARKET,BY THERAPEUTIC AREA,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CANCER AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OTHERS AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)

FIGURE 15.AUTOLOGOUS CELL THERAPY MARKET,BY END USER,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CANCER TREATMENT CENTERS AUTOLOGOUS CELL THERAPY MARKET,2021-2031(%)

FIGURE 18.AUTOLOGOUS CELL THERAPY MARKET BY REGION,2021

FIGURE 19.U.S. AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 20.CANADA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 21.MEXICO AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 22.GERMANY AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 23.FRANCE AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 24.UK AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 25.ITALY AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 26.SPAIN AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 27.REST OF EUROPE AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 28.JAPAN AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 29.CHINA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 30.INDIA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 31.AUSTRALIA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 32.SOUTH KOREA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 33.REST OF ASIA-PACIFIC AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 34.LATIN AMERICA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 35.MIDDLE EAST AND AFRICA AUTOLOGOUS CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 36. TOP WINNING STRATEGIES, BY YEAR

FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 40.COMPETITIVE DASHBOARD

FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 42.BRISTOL MYERS SQUIBB.: NET SALES ($MILLION)

FIGURE 43. NOVARTIS.: NET SALES ($MILLION)

FIGURE 44.VERICEL CORPORATION.: NET SALES ($MILLION)

FIGURE 45. GILEAD SCIENCES (KITE PHARMA, INC.).: NET SALES ($MILLION)

FIGURE 46. JOHNSON & JOHNSON(JANSSEN BIOTECH, INC).: NET SALES ($MILLION)

FIGURE 47.TEGO SCIENCE.: NET SALES ($MILLION)

FIGURE 48.SANPOWER GROUP (DENDREON PHARMACEUTICALS LLC.).: NET SALES ($MILLION)

FIGURE 49.HOLOSTEM TERAPIE AVANZATE S.R.L..: NET SALES ($MILLION)

FIGURE 50.GC BIOPHARMA (GC CELL).: NET SALES ($MILLION)

FIGURE 51.CORESTEM, INC.: NET SALES ($MILLION